$3.52
Vaccitech is a biotechnology business based in the US. Vaccitech shares (VACC) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccitech employs 33 staff and has a trailing 12-month revenue of around $13.4 million.
Our top picks for where to buy Vaccitech PLC ADR stock
How to buy Vaccitech stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VACC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Vaccitech stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Vaccitech stock price (NASDAQ: VACC)
Use our graph to track the performance of VACC stocks over time.Vaccitech shares at a glance
Latest market close | $3.52 |
---|---|
52-week range | $1.64 - $5.10 |
50-day moving average | $3.14 |
200-day moving average | $2.58 |
Wall St. target price | $9.31 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.45 |
Is it a good time to buy Vaccitech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Vaccitech price performance over time
Historical closes compared with the close of $3.52 from 2023-12-26
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-07) | 92.35% |
---|---|
2 years (2022-09-07) | -8.57% |
3 years (2021-09-07) | 14.93 |
5 years (2019-09-03) | N/A |
Vaccitech financials
Revenue TTM | $13.4 million |
---|---|
Gross profit TTM | $44.7 million |
Return on assets TTM | -15.2% |
Return on equity TTM | -23.29% |
Profit margin | 0% |
Book value | $5.64 |
Market Capitalization | $192.7 million |
TTM: trailing 12 months
Vaccitech share dividends
We're not expecting Vaccitech to pay a dividend over the next 12 months.
Vaccitech share price volatility
Over the last 12 months, Vaccitech's shares have ranged in value from as little as $1.64 up to $5.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccitech's is -0.393. This would suggest that Vaccitech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vaccitech has bucked the trend.
To put Vaccitech's beta into context you can compare it against those of similar companies.
- Applied Molecular Transport Inc (AMTI.US): 2.286
- Brainstorm Cell Therapeutics (BCLI.US): 0.36
- Neximmune (NEXI.US): 1.85
Vaccitech overview
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021.
Frequently asked questions
What percentage of Vaccitech is owned by insiders or institutions?Currently 3.457% of Vaccitech shares are held by insiders and 49.837% by institutions. How many people work for Vaccitech?
Latest data suggests 33 work at Vaccitech. When does the fiscal year end for Vaccitech?
Vaccitech's fiscal year ends in December. Where is Vaccitech based?
Vaccitech's address is: The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE What is Vaccitech's ISIN number?
Vaccitech's international securities identification number is: US91864C1071
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question